International Journal of Risk & Safety in Medicine

Patient Safety - Pharmacovigilance - Liability


33, 4 issues

Latest issue

32:4 online 05 November 2021

Next issue

33:1 scheduled for February 2022

Back volumes

From volume 1, 1990

ISSN print


ISSN online


Aims & Scope

The International Journal of Risk and Safety in Medicine is concerned with rendering the practice of medicine as safe as it can be; that involves promoting the highest possible quality of care, but also examining how those risks which are inevitable can be contained and managed. This is not exclusively a drugs journal. Recently it was decided to include in the subtitle of the journal three items to better indicate the scope of the journal, i.e. patient safety, pharmacovigilance and liability and the Editorial Board was adjusted accordingly. For each of these sections an Associate Editor was invited. We especially want to emphasize patient safety. Our journal wants to publish high quality interdisciplinary papers related to patient safety, not the ones for domain specialists. For quite some time we have also been devoting some pages in every issue to what we simply call WHO news. This affinity with WHO underlines both the International character of the journal and the subject matter we want to cover. Basic research, reports of clinical experience and overviews will all be considered for publication, but since major reviews of the literature are often written at the invitation of the Editorial Board it is generally advisable to consult with the Editor in advance. Submission of news items will be appreciated, as will be the contribution of letters on topics which have been dealt with in the journal.

Editorial Board


I. Ralph Edwards
Professor in Medicine
Uppsala Monitoring Centre, 


Marie Lindquist
WHO Collaborating Centre for
International Drug Monitoring, 


Former Editor-in-Chief

C.J. van Boxtel

Founding Editor

M.N.G. Dukes

Associate Editors

Clinical Pharmacology and Evidence-Based Medicine

Liliya E. Ziganshina
Kazan Federal University
Liliya E. Ziganshina, Kazan Federal University, Kazan, Russian Federation

Patient Safety

Mecit Can Emre Simsekler
Boston Children’s Hospital, Boston, MA


Federico Laus
University of Bologna

Pharmaceuticals Policy and Law

Carlo Bottari
University of Bologna
Bologna, Italy

Editorial Board

Elliot Brown
Medicine, Clinical Pharmacology and Regulatory Affairs
Elliot Brown Consulting Ltd, Leeds, UK

Rebecca Chandler
Pharmacovigilance, Infectious Diseases and Vaccines
Uppsala Monitoring Centre, Uppsala, Sweden

Andrzej Czarnecki
Pharmacovigilance and Internal Medicine
Eli Lilly and Company, Windlesham, UK

Edzard Ernst
Complementary Medicine
University of Exeter, Exeter, UK

Maxine Gossell-Williams
Pharmacologist and Educator
The University of the West Indies at Mona, Kingston, Jamaica

Ulrich Hagemann
Drug Commission of the German Medical Association, Berlin, Germany

Rokuro Hama
Internal Medicine and Patient Safety
Japan Institute of Pharmacovigilance, Osaka, Japan

Donald Harvey Marks
Internal Medicine and Microbiology
University of Pittsburgh, Pittsburgh, PA, USA

Ambrose Isah
Medicine and Clinical Pharmacology
University of Benin, Benin, Nigeria

Jesse Lyle Bootman
Pharmaceuticals Policy and Law
Tabula Rasa Health Care, Moorestown, NJ, USA

John McEwen
Pharmacovigilance and Neurology
Therapeutic Goods Administration, Canberra, Australia

Michael Napier
Class Action Law and Medication Injuries
Legal Consultant, London, UK

Emmanuel Okoro
Medicine and Clinical Pharmacology
Covenant University Ota, Ota, Nigeria

Abimbola Olowofela-Opadeyi
Clinical Pharmacology and Therapeutics
University of Benin, Benin, Nigeria

Priscilla Patricia Nyambayo
Pharmacovigilance and Clinical Trials
Munyaradzi Medicines Control Authority of Zimbabwe, Harare, Zimbabwe

Eugène van Puijenbroek
University Groningen, Groningen, The Netherlands

Peter R. Breggin
Private Practice of Psychiatry, Clinical Psychopharmacology and Forensics, Ithaca, NY, USA

Elena Rocca
Philosophy of Science and Health Care
NMBU University, Ås, Norway

Mulugeta Russom
Eritrean Pharmacovigilance Centre, Asmara, Eritrea

Ruth Savage
Clinical Pharmacology and Epidemiology
University of Otago, Christchurch, New-Zealand

Anders Sundström
Karolinska Institutet, Solna, Sweden

Michael Tatley
Pharmacovigilance, Public Health and Vaccines
Otago University, Dunedin, New Zealand

Adam Urato
Maternal and Fetal Medicine
MetroWest Medical Center, Framingham, MA, USA

Mauro Venegoni
Internal Medicine and Pharmacovigilance
University of Verona, Verona, Italy

Author Guidelines


By submitting my article to this journal, I agree to the Author Copyright Agreement, the IOS Press Ethics Policy, and the IOS Press Privacy Policy.

Authors are requested to submit their paper through the journal’s online submission system.

Submission of an article is understood to imply that the article is original and unpublished and is not being considered for publication elsewhere.

Please take a moment to read the IOS Press general publication ethics guideline before submitting your manuscript.

Publication fee
The International Journal of Risk & Safety in Medicine does not charge a publication fee.

Required files
The following electronic files are required:
- a Word processor file of the text, such as Word, WordPerfect, LateX (If using LaTeX, please use the standard article.sty as a style file and also send a pdf version of the LaTeX file)
- separate files of all figures (if any); see "Preparation of manuscripts" for the required file formats.

Colour figures
It is possible to have figures printed in colour, provided the cost of their reproduction is paid for by the author. See Preparation of Manuscripts for the required file formats.


Organization of the paper and style of presentation
Manuscripts must be written in English. Authors whose native language is not English are advised to seek the advice of a native English speaker, before submitting their manuscripts.

Peerwith offers a language and copyediting service to all scientists who want to publish their manuscript in scientific peer-reviewed periodicals and books.

Manuscripts should be prepared with wide margins and double spacing throughout, including the abstract, footnotes and references. Every page of the manuscript, including the title page, references, tables, etc., should be numbered. However, in the text no reference should be made to page numbers; if necessary, one may refer to sections. Try to avoid the excessive use of italics and bold face.

Manuscripts should be organized in the following order:

  • Title page
  • Body of text (divided by subheadings)
  • Acknowledgements
  • References
  • Tables
  • Figure captions
  • Figures
  • Headings and subheadings should be numbered and typed on a separate line, without indentation.

    SI units should be used, i.e., the units based on the metre, kilogramme, second, etc.

    Title page
    The title page should provide the following information:

  • Title (should be clear, descriptive and not too long)
  • Name(s) of author(s); please indicate who is the corresponding author
  • Full affiliation(s)
  • Present address of author(s), if different from affiliation
  • Complete address of corresponding author, including tel. no., fax no. and e-mail address
  • Abstract
  • Keywords
  • Abstract
    The abstract should be clear, descriptive, self-explanatory and not longer than 200 words, it should also be suitable for publication in abstracting services.
    The abstract for research papers should follow the “structured abstract” format. Section labels should be in bold uppercase letters followed by a colon, and each section will begin on a new line.

    Number as Table 1, Table 2 etc, and refer to all of them in the text.

    Each table should be provided on a separate page of the manuscript. Tables should not be included in the text.

    Each table should have a brief and self-explanatory title.

    Column headings should be brief, but sufficiently explanatory. Standard abbreviations of units of measurement should be added between parentheses.

    Vertical lines should not be used to separate columns. Leave some extra space between the columns instead.

    Any explanations essential to the understanding of the table should be given in footnotes at the bottom of the table.


    Number figures as Fig. 1, Fig. 2, etc and refer to all of them in the text.

    Each figure should be provided on a separate sheet. Figures should not be included in the text.

    Colour figures can be included, provided the cost of their reproduction is paid for by the author.

    For the file formats of the figures please take the following into account:

  • Line art should be have a minimum resolution of 600 dpi, save as EPS or TIFF
  • Grayscales (incl photos) should have a minimum resolution of 300 dpi (no lettering), or 500 dpi (when there is lettering); save as tiff
  • Do not save figures as JPEG, this format may lose information in the process
  • Do not use figures taken from the Internet, the resolution will be too low for printing
  • Do not use colour in your figures if they are to be printed in black & white, as this will reduce the print quality (note that in software often the default is colour, you should change the settings)
  • For figures that should be printed in colour, please send a CMYK encoded EPS or TIFF
  • Figures should be designed with the format of the page of the journal in mind. They should be of such a size as to allow a reduction of 50%.

    On maps and other figures where a scale is needed, use bar scales rather than numerical ones, i.e., do not use scales of the type 1:10,000. This avoids problems if the figures need to be reduced.

    Each figure should have a self-explanatory caption. The captions to all figures should be typed on a separate sheet of the manuscript.

    Photographs are only acceptable if they have good contrast and intensity.

    Conflict of Interest Statement

    A Conflict of Interest Statement asks authors to disclose four types of information:

    (1) Associations with commercial entities that provided support for the work reported in the submitted manuscript (the timeframe for disclosure in this section of the form is the lifespanof the work being reported).
    (2) Associations with commercial entities that could be viewed as having an interest in the general area of the submitted manuscript (in the 36 months before submission of the manuscript).
    (3) Any similar financial associations involving authors’ spouses, partners, their children under 18 years.
    (4) Non-financial associations that may be relevant to the submitted manuscript.

    Informed Consent Statement

    For research, statements are needed regarding ethics approval (or a statement that it was not required) and of seeking informed consent from participants; funding; the role of the study sponsor in study design and the collection, analysis, and interpretation of data and the writing of the article and the decision to submit it for publication; the independence of researchers from funders and sponsors; and the access of researchers to all the data.


    1. Place citations as numbers in square brackets in the text. All publications cited in the text should be presented in a list of references following the text of the manuscript. Only articles published or accepted for publication should be listed in the reference list. Submitted articles can be listed in the text as (author(s), unpublished data).

    2. All authors should be listed in the reference list.

    3. References must be listed in Vancouver style:

    [1] Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, Kochanek PM, Graham SH. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002; 935(12): 406.
    [2] Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.
    [3] Berkow R, Fletcher AJ, editors. The Merck manual of diagnosis and therapy. 16th ed. Rahway (NJ): Merck Research Laboratories; 1992.
    [4] Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGrawHill; 2002. p. 93113.
    [5] Canadian Cancer Society [homepage on the Internet]. Toronto: The Society; 2006 [updated 2006 May 12; cited 2006 Oct 17]. Available from:

    Footnotes should only be used if absolutely essential. In most cases it is possible to incorporate the information in the text.
    If used, they should be numbered in the text, indicated by superscript numbers and kept as short as possible.


    Copyright of your article
    Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.

    Quoting from other publications
    An author, when quoting from someone else's work or when considering reproducing figures or table from a book or journal article, should make sure that he is not infringing a copyright. Although in general an author may quote from other published works, he should obtain permission from the holder of the copyright if he wishes to make substantial extracts or to reproduce tables, plates or other figures. If the copyright holder is not the author of the quoted or reproduced material, it is recommended that the permission of the author should also be sought. Material in unpublished letters and manuscripts is also protected and must not be published unless permission has been obtained. Submission of a paper will be interpreted as a statement that the author has obtained all the necessary permission. A suitable acknowledgement of any borrowed material must always be made.


    PDF Proofs
    The corresponding author will receive a pdf proof and is asked to check this proof carefully (the publisher will execute a cursory check only). Corrections other than printer's errors, however, should be avoided. Costs arising from such corrections will be charged to the authors.

    How to order reprints, a pdf file, journals, or IOS Press books
    For each contribution the corresponding author will receive a complimentary Author’s Copy (watermarked) pdf of their published article. This pdf is for personal use only. Free copies will not be provided for conference proceedings and abstract issues. An order form for reprints, additional journal copies or a pdf file will be provided along with the pdf proof.

    If you wish to order reprints of an earlier published article, please contact the publisher for a quotation. IOS Press, Fax: +31 20 6870039. Email:

    An author is entitled to 25 % discount on IOS Press books. See Author's Discount (25%) on all IOS Press book publications.


    Authors of published articles (non-prepress, final articles) will be contacted by Kudos. Kudos is a service that helps researchers maximize the impact and visibility of their research. It allows authors to enrich their articles with lay metadata, add links to related materials and promote their articles through the Kudos system to a wider public. Authors will receive no more than three emails: one invitation and a maximum of two reminders to register for the service and link the published article to their profile. Using and registering for Kudos remains entirely optional. For more information, please have a look at our authors section.


    Would you like some pointers on how to help your research achieve a wider reach and greater impact? Please consult our Promotional Toolkit for Authors for tips.


    Abstracted/Indexed in

    Academic Search
    Biomedical Reference Collection
    CAB Abstracts
    CSA Illumina
    e-psyche database
    EBSCO Databases
    Elsevier BIOBASE
    Environment Complete
    EVISA - European Virtual Institute for Speciation Analysis
    Global Health
    Index Medicus
    International Pharmaceutical Abstracts
    OA @ PubMedCentral
    Risk Abstracts
    SciVerse Scopus
    Ulrich's Periodicals Directory
    Web of Science: Emerging Sources Citation Index

    Peer Review Policy

    The International Journal of Risk & Safety in Medicine is a peer-reviewed journal. Articles submitted to the journal undergo a single-blind peer review process. This means that the identity of the authors is known to the reviewers but the identity of the reviewers is not communicated to the authors.

    All submitted manuscripts are subjected to initial appraisal by the Editors-in-Chief and, if found suitable for further consideration, to rigorous peer review by independent, anonymous expert referees. Reasons to reject a paper in the pre-screening process could for example be that the work does not fall within the aims and scope, the writing is of poor quality, the instructions to authors were not followed or the presented work is not novel.

    Papers deemed suitable to be reviewed will be assigned to a handling editor. The handling editor will then invite reviewers to comment on the work and might consider inviting the reviewers suggested by the author(s). Editors and reviewers are asked to excuse themselves from reviewing a submission if a conflict of interest makes them unable to make an impartial scientific judgment or evaluation. Conflicts of interest include but are not limited to: collaboration with the authors in the past three years; any professional or financial affiliations that may be perceived as a conflict of interest; a history of personal differences with the author(s).

    As a standard policy, decisions are based on three reviews, in some specific circumstances a minimum of two reviews may be deemed sufficient to make a decision on a paper. The Editors-in-Chief strive to ensure a typical turnaround time of three months.

    Reviewers are asked to judge a paper on at least:

    • Logical, concise ordering of ideas
    • Use of sound research methods
    • Adequacy of documentation    
    • Material has good applied use in the field    
    • Readability and interest level

    Based on the received reviews the handling editor will propose to the Editors-in-Chief a recommendation:

    1. Accept article as submitted
    2. Accept article revision by the author according to suggestions made in review
    3. Revise and resubmit
    4. Reject
    5. Consider for another issue/publication

    They mean the following:

    1. The manuscript is suitable for publication and only requires minor polishing; thus, no further reviews are requested.
    2. The authors are required to make moderate changes to their manuscript. The manuscript becomes acceptable for publication if the changes proposed by the reviewers and editors are successfully addressed. The revised manuscript will be examined by the Editors-in-Chief and possibly sent back to all (or a selection of) reviewers for a second round of reviews. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
    3. In its current form, the manuscript is not suitable for publication. A resubmission would require substantial revisions and is only encouraged in special cases. The resubmitted manuscript will be considered as a new submission.
    4. The manuscript is rejected as it is deemed to be out of scope, not relevant, or not meeting the journal’s quality standards in terms of significance, novelty, and/or presentation.
    5. The manuscript is rejected as it is deemed to be better suited for a different journal or publication.

    Authors are notified by the Editors-in-Chief, whose decision is final.

    Former Editor-in-Chief of The International Journal of Risk & Safety in Medicine, Prof. Dr. Christoffel Jos van Boxtel, has passed away on the 23rd of January 2020. He will be greatly missed. We have published an In Memoriam, which can be found here. We are very pleased to announce that the Editor-in-Chief of The International Journal of Risk & Safety in Medicine, I. Ralph Edwards, was awarded the Honorary Doctor of Science Degree by the University of Benin, Nigeria in 2020. We congratulate him on this achievement. For more information, please see here.

    The International Journal of Risk & Safety in Medicine is putting out a call for papers on the following topics: Evaluations of the risks versus benefits of any medical intervention Understanding and communication of vaccine risks Understanding and communication of uncertainty in medicines Risk and harm of medical care to clinical care practitioners